Summary.-This study analyses the activity of 95 antisera raised in rabbits against human leukaemic myeloblasts. A number of different means were used to immunize both normal rabbits and rabbits which had been treated to render them tolerant of normal human splenic leucocytes. Different immunization schedules included the use of different doses of untreated myeloblasts, as well as myeloblasts treated with neura -
1251-horse-F(ab')2-anti-rabbit-Fab and a K-cell-mediated cytotoxicity test using rat spleen cells as effectors.
(i) The unabsorbed sera showed similar mean titres against leukaemic myeloblasts and normal splenocytes.
(ii) Extensive absorption with pooled cadaveric spleen were required to remove antibody against polymorphic antigens.
(iii) 17/95 antisera had activity against at least some leukaemic myeloblasts after extensive absorption with cadaveric spleen.
(iv) Some of the 17 absorbed sera with selective activity for myeloblasts also reacted against PHA-induced lymphoblasts.
(v) Although the 17 absorbed sera showed little or no activity against marrow in the above assays normal human marrow totally absorbed all residual activity in these sera against leukaemic myeloblasts.
We conclude that although these sera contain activity against antigens common to leukaemic myeloblasts and a minority population of normal marrow cells, they have no detectable activity against leukaemia-specific antigens.
DESPITE much circumstantial evidence for their presence, the existence of human tumour-specific antigens remains a tentative proposition. Nevertheless, over the years there have been several reports of the production of heterologous antisera specific for leukaemia-associated antigens in acute myeloblastic leukaemia (AML) and other leukaemias (Garb et al., 1962; Hyde et al., 1967; Mann et al., 1971; Mann et al., 1974; Metzgar et al., 1972; Mohanakumar et al., 1974; Baker et al., 1974; Durantez et al., 1976) . In addition, stimulation of lymphocyte blastogenesis 33 by leukaemic cells, particularly in the autologous situation (Fridman and Kourilsky, 1969; Viza et al., 1969; Powles et al., 1971; Taylor et al., 1976) and in HL-Aidentical siblings (Fefer et al., 1976) has been presented as evidence for the existence of these antigens. These findings have generated much interest in the possibility of exploiting these leukaemia antigens in active immunotherapy to prolong the duration of clinical remission in AML (Powles et al., 1973; Freeman et al., 1973; Powles et al., 1977) .
L. TIUPCHONGx AND I. C. M. MACLENNAN monly associated with B-cells (Ia antigens) (Arbeit et al., 1975; Mann et al., 1975a) have been reported on the surface of a high proportion of acute leukaemia cells (Fu et al., 1975; Schlossmann et al., 1976; Billing et al., 1976 Billing et al., , 1977 . It is clear that several antisera which were previously reported to be specific for leukaemia are, in fact, directed against these antigens (Billing et al., 1976; Zighelboim et al., 1977) . Furthermore, the stimulation of atutologous and HL-A-identical peripheral blood lymphocytes by leukaemic cells may be related to the presence of these antigens on leukaemic cells (Opelz et al., 1977) . Autologous MLC stimulation by normal lymphocyte subpopulations occurs in analogous conditions with a high T-cell-responding cell population and a B-cell-enriched stimulating population (Lohrmann et al., 1974; Opelz et al., 1975 ; Kuntz et al., 1976) and antisera against Ia antigens inhibit these reactions (Cresswell and (Geier, 1975) .
In this report we describe attempts to confirm the presence of leukaemia-specific antigens, by producing rabbit antisera against human leukaemic myeloblasts by a variety of techniques. The specificities of the heterologous antisera produced against AML have been analysed by 2 sensitive techniques, a K-cell-mediated cytotoxicity test and a non-cytotoxic radio-immune anti-immunoglobulin binding technique. The results suggest that the surface antigenic make-up of leukaemic myeloblasts is qualitatively normal. The antigenic determinants present on leukaemic myeloblasts include those wlhich are characteristic for a minority population of normal marrow cells. There is also evidence for antibodies in these AML antisera which are reactive with PHAstimulated lymphoblasts and which cannot be absorbed out by splenic lymphoid cells. If leukaemia-specific antigens common to most patients with AML exist, they are either non-immunogenic in the animals studied or are below the resolution of the tests used for their detection in this study.
METHODS AND MATERIALS
Patients. These w%ere adults admitted to the Radcliffe Infirmary, Oxford, which was one of the centres involved in the recent British Medical Research Council's 6th AML Immunotherapy Trial. The diagnosis of acute myeloblastic leukaemia (AML) was made on cliiiical grounds, and on conventional morplhological criteria and cytochemistry wAith Sudan Black B, PAS and Romanovsky stains (Hayhoe et al., 1964) . Patients were selected for study only if they had at least 90°(U myeloblasts in the peripheral blood.
Collection and storage of myeloblasts.-Blood w-as taken into heparin or acid-citrate dextrose from each patient at clinical presentation before chemotherapy Awas instituted. Myeloblasts w-ere separated from peripheral blood and marrow aspirates by Ficoll-Triosil gradient centrifugation (Boyum, 1968) or after the sedimentation of blood under 1 g and the removal of the leucocyterich plasma. The cells wrere washed twice in pre-heated normal saline (37°C) to remove free plasma and passively carried proteins and then resuspended in RPMI 1640 (GibcoBiocult, Paisley) which was supplemented with 10% foetal calf serum, 1% non-essential amino acids, 2 mm fresh glutamine, penicillin and streptomycin. Dimethyl sulphoxide was added to the cell suspension to a final concentration of 10%. The cells were then rapidly dispensed into polycarbonate ampoules (Sterilin, Surrey) and then cooled at 1-2°C/min until the temperature had been lowNered to -60°C. The ampoules were then stored over liquid N2.
The cells wNere thawed rapidly in a 37°C waterbath and diluted gradually w-ith prewarmed normal saline + 10% FBS before use. They were wAashed twice w-ith normal saline. The viability of intact cells after thawing, as assessed by trypan-blue dye exclusion and phase microscopy was 70- (Tupchong, 1978) . Before use, spleens were thawed at 37 0C, homogenized in a moule (Mouli-baby grinder) and thoroughly washed with phosphatebuffered saline.
Marrow.-Fresh marrow cells were obtained from ribs removed from patients undergoing thoracotomy for non-malignant conditions. As target cells, they were used fresh or after storage in liquid N2 after controlled-rate freezing. When used for absorption purposes, they were lightly fixed with glutaraldehyde (0-25%) (Avrameas and Ternynck, 1969) Induction of tolerance of human spleen cells. -(1) Neonatal injection with human cells: Neonatal rabbits were injected i.p. within 3 h of birth with 1-2 x 108 human spleen cells (carefully cryopreserved from ruptured spleens). Injections were given daily for 12 days and then every 2 days for a week. In some rabbits this was followed by twice-weekly injections until 4 weeks after birth. When rabbits were test-bled at one month of age, all had some antibody against splenocytes, and the degree of tolerance achieved was in some doubt. In further attempts to induce tolerance in these animals, cyclophosphamide (Endoxana, Wellcome, Kent) (100 mg/kg) was given i.p. together with 108 splenic lymphocytes. In several rabbits (see Table I ), the cyclophosphamide was repeated either alone or with splenic lymphocytes every 2 weeks. (ii) Neonatal injection with soluble human antigen: Soluble human antigen was prepared by 3M KCI extraction (Reisfeld and Kahn, 1971) from 5 x 109 normal splenic lymphocytes. The preparation was ultracentrifuged at 160,000 g for 90 min and the supernatant was tested for its ability to inhibit the action of an anti-lymphocytic serum against the original splenic lymphocytes as target cells. Neonatal rabbits were injected i.p. daily with 10 mg of the soluble extract for 10 days. They were test bled at one month and challenged with cyclophosphamide and normal splenic lymphocytes. At this stage, none of the rabbits which were injected with soluble material had antibody against normal splenocytes. (iii) Attempts to induce tolerance in adult rabbits: Adult rabbits were injected i.p. at 3 months of age with cyclophosphamide (100 mg/kg) together with 1-2 x 108 splenic lymphocytes.
Irrespective of the method used to induce tolerance, all rabbits were injected 14 days after the last injection of cyclophosphamide with 108 leukaemic myeloblasts and this was repeated thrice at 14-day intervals. In some animals, the immunizing myeloblasts were coated with NABS prior to injection.
Control antisera.-The following immunerabbit antisera were used as controls in the absorption procedures: an anti-human-lymphocyte serum, an anti-human-marrow serum, an anti-C3H mouse L-strain-fibroblast serum and an anti-C3H mouse benzopyrene-induced-sarcoma serum.
Absorption of antisera. used. After labelling, the cells were washed in medium through a gradient of FBS carefully layered at the bottom of the container.
The assays K-cell-mediated cytotoxicity.-Heat-inactivated antisera were serially diluted 1:3 in 100 ,u BME in Cooke microtitte plates. Fifty microlitres of rat spleen cells from Lewis rats (RSC, 6 x 107 cells/ml) were added, followed by 50 pul 5Cr-labelled target cells (4 x 105 cells/ml).
Controls consisted of (i) target cells, RSC and medium without antibody (baseline release-6 readings); (ii) target cells, RSC and a known positive antiserum, diluted 1/20, which was at the plateau of cytotoxicity.
The plates were sealed with non-toxic adherent plastic film and incubated for 6 h at 37°C. They were then centrifuged at 200 g for 5 min and 150 ,ul of the supernatant from each well was transferred to small plastic tubes for counting in an automatic Wallac gamma-counter. Six tubes were also added which contained the total activity added to each well. e.2= standard error of mean of baseline readings. The last dilution ofthe antiserum producing significant 51Cr release above baseline (P < 0.05) was taken as the end-point titre of the antiserum. We are grateful to Dr G. T. Warner for preparing the computer programme.
'25Iodinated horse anti-rabbit (125I-HAR) binding assay.-A horse anti-rabbit serum (generous gift of Dr A. F. Williams, Department of Biochemistry, Oxford) was purified by elution from a Sepharose 4B immunoabsorbent column (rabbit IgG), followed by pepsin degradation. Pepsin (Sigma) was added at 4 mg/100 mg protein for 20 h at 37°C in 01M sodium acetate buffer, pH 4*5.
The mixture was then passaged through a Sephadex G200 filtration column. The F(ab')2 peak was taken and iodinated using a low dose of chloramine T (BDH) (10-20 jug per 25 ,ug protein) using the technique of Jensenius and Williams (1974) .
The assay was performed in round-bottomed Cooke microtitre plates (Sterilin). To standard 3-fold dilutions of heat-inactivated antiserum in MEM was added live target cells at , 5 x 105 cells per well. After preincubation of the antibody and target cells for 1 h at 0-40C, the cells were washed x 3 with PBS + 1% BSA and 0 02% azide. The radio-labelled HAR antibody was then added to the pelleted cells at 300,000-400,000 ct/min. The cells were resuspended and left for a further 60 min, after which they were washed x 3. The final pellet was dissolved in 100 ,ul NaOH (0*1M) and transferred to small plastic tubes for gamma-counting.
RESULTS
General plan for assessing specificity of antisera raised against leukaemic myelo- Before any absorption, the antisera were tested for their capacity to induce cytolysis by rat spleen K-cells against a standard test leukaemic-myeloblast preparation and a test normal splenic-lymphocyte preparation. All antisera had strong activity against both, with the mean end-point titre against the myeloblasts ± 1 s.d. being 38.12±1.24 and against the splenic lymphocytes 37.58+1.96
The antisera were next passed throuLgh a series of absorptions against pooled cadaveric human spleen cells. Some sera were also absorbed against erythrocytes and platelets, but analysis of the absorptive 485 capacity of these agents showed them to be less efficient in this context than splenocytes. Up to 8 absorptions with cadaveric spleens were made on each antiserum. The first 2 absorptions were against an equal volume of a single pool of 52 cadaveric spleens; absorption 3 was against an equal volume of a further pool of 50 spleens; absorption 4 against a pool of 50 spleens; absorption 5 against 11 spleens; absorption 6 against 6 spleens; absorption 7 against 21 spleens and absorption 8 against 8 spleens. After the second and subsequent absorptions, the antisera were tested for K-cell cytotoxic activity against at least two myeloblast preparations (Myeloblast 2: HL-A A2, AW32, BW35, BW40. Myeloblast 11:
HL-A Al, A3, B8, B17) and two splenic lymphocyte preparations (ly 1: HL-A Al, A2, B8, Ly 8: HL-A A2. A3, BW12, BW35). Absorption proceeded until either the antisera were positive against at least one of the myeloblasts and negative against the lymphocytes, or they were negative against both. Seventeen of the original antisera were found to be positive against at least one of the myeloblasts, while failing to induce K-cell-mediated cytolysis against the lymphocytes. These antisera then went forward for more detailed analysis against a variety of normal and leukaemic cells. At this stage the 1251-anti-rabbit immunoglobulin assay was also used. Finally, these 17 antisera were absorbed against human marrow . . , , , " . After the second and subsequent splenic absorption stages, all sera were tested against two myeloblast preparations (My2 and Myl 1) and 2 lymphocyte preparations. Seventeen antisera were found which had no K-cell activity against the lymphocyte preparations, but which reacted against at least one of the 2 myeloblast preparations. Table III shows for these 17 antisera the mode of immunization, the immunizing myeloblast and the number of absorptions required to remove activity against the screening lymphocytes. The first detailed screen used for these antisera was to test their ability to Table IV , which shows that none of the antisera was fully specific for myeloblasts and, as in the preliminary screen, the overall pattern strongly indicated marked activity against polymorphic antigens.
It was felt to be impractical to proceed to further absorption at this stage, and a 14 15 16 17   FIG. 3a, b and c.-Binding of absorbed AML+ antisera to leukaemic myeloblasts and PHA-stimulated remission cells from 3 donors, before and after absorption with normal bone marrow. The antisera were tested against equal numbers of target myeloblasts and target remission cells in the same experiment. * 0 activity against the myeloblasts; * O activity against the PHA-stimulated remission cells; 0 * activity before the marrow absorption; 0 --O activity after the marrow absorption. The control antisera which had all been absorbed x 5 with cadaveric spleen were: A: anti-lymphocytic antiserum. B: anti-marrow serum. C: anti-C3H mouse strain-L fibroblast. Lines which are longer than the control antisera indicate increased specificity for the leukaemic myeloblasts. In Fig. 3a these are shown by sera 1, 4, 6, 8, 11, 13 and 15 before absorption with marrow, and serum 2 after absorption. In Fig. 3b , these are sera 1, 2, 4, 5, 6, 12, 14 and 16 before absorption and serum 6 also after absorption, but this is not seen against the myeloblasts of 3a and 3c. In Fig. 3c only sera 13 and 14 show increased activity against AML blasts before absorption. The effect of niarrow absorption The last experiment described above gives some indication that antibody might exist in some of the sera which have specificity, as assessed by K-cell-mediated cytotoxicity, against leukaemic myeloblasts. Normal myeloblasts, however, are a minority population in marrow and cytotoxic assays on the whole marrow might not detect activity against them. Consequently, we subjected all 17 of the sera to 2 absorptions against equal volumes of normal marrow. This resulted in complete loss of selective activity against myeloblasts and PHA-stimulated remission lymphocytes from the same patient. We concluded at this stage that the K-cellmediated cytotoxicity assay was detecting specificity in these antisera which was directed only against normal tissue antigens.
The 1251-anti-immunoglobulin assay used to assess the activity in the selected A ML+ antisera
The same principle as used above (the testing of myeloblasts in parallel with PHA-stimulated lymphoblasts from the same donor) was adopted for assessing antisera with a radioactive anti-rabbit immunoglobulin reagent (1251-HAR). Three pairs of myeloblasts and autologous lymphoblasts were tested for antigens which bound the 17 antisera both before and after double marrow absorption. The results are shown in Fig. 3a, b (Mohanakumar et al., 1974; Mann et al., 1974; Baker and Taub, 1973; Durantez et al., 1976) , our results do not provide support for the concept of immunogenic leukaemia-specific antigens in AML. Despite the exhaustive testing of a large number of heterologous antisera, produced in a variety of ways, we have not been able to develop an antiserum which has potent activity against leukaemic myeloblasts but no significant activity against normal tissues. Although the AML titre of the antisera before absorption varied from 1/39,000 to 1/300,000, all the activity could be removed by absorption with splenic lymphocytes and marrow cells. Splenic lymphocytes alone were able to remove much of this activity, indicating that common antigens between lymphocytes and leukaemic myeloblasts are responsible for most of the anti-AML activity in the AML antisera. Fu et al. (1975) , Billing et al. (1976; reported that a high proportion of undifferentiated lymphoblastic and myeloblastic leukaemias react with antisera directed against human Ia-like antigens. These HL-A Dlocus antigens are not present on normal blood T cells or T blasts. Consequently, assays with a high cut-off point for cytotoxicity will find anti-Ia sera negative for blood lymphocytes but positive for most myeloid leukaemic cells. This might explain much of the activity which was present in previously reported anti-leukaemic antisera. Similarly, antisera raised with cells from B lymphoblastoid cell lines (e.g. RAJI) 1975b; Durantez et al., 1976) as well as spontaneous anti-leukaemic antibody found in normal individuals (Bias et al., 1972; Cullen and Mason, 1976 ) might be attributable to these antigens. Despite the large number of reports suggesting that leukaemia-specific antigens exist, some investigators have failed to find antibody specific for antigens found exclusively on AML blasts, for example, in human subjects undergoing active immunotherapy (Gale and MacLennan, 1977; Klouda et al., 1975) . Also, one worker raising antisera against AML blasts (Greaves, 1975) failed to confirm the presence of tumour-specific antigens in this disease.
Analysis of the AML antisera in this study, therefore, reveals that they recognize cell-surface antigens on leukaemic myeloblasts which are essentially, if not completely, equivalent to normal antigens found on splenic lymphocytes and marrow cells. This includes activity against human alloantigens as well as against cell-cycleassociated antigens present on PHAstimulated remission lymphocytes but not on unstimulated cells. The increase in reactivity against PHA-stimulated cells was not explained by increased susceptibility to cytotoxic lysis, since this activity was also shown by the 125iodinated anti-immunoglobulin assay. Only a small fraction of the total activity of the antisera was directed against putative myeloid differentiation antigen, suggesting that they may not be prominent on the cell-surface of these cells. Marrow was extremely effective in removing residual activity (against both leukaemic myeloblasts and PHA-induced lymphoblasts) which remained after absorption with splenic lymphocytes. Spleen cells were used because of the availability of this tissue at post-mortem, and the presence of a high proportion of B cells expressing HL-A D-locus antigens and mature myeloid cells. Because of the heterogeneity of cells in marrow preparations, it is difficult to specify from these studies which cells were particularly responsible for removing the residual anti-myeloblastic activity. However, failure to absorb activity with spleen militates against this activity being on a mature myeloid cell. The low level of cytotoxicity induced against marrow cells by the 17 final antisera, before their absorption with marrow, suggests that the absorbing antigen in marrow is on a minority of cells. The antisera which showed most residual activity against AML blasts after spleen tissue absorption were produced: (1) following modification of the immunizing cells with neuraminidasetreatment of NABS-coating, or (2) by immunization of animals in which induction of tolerance against normal antigens had been attempted. Detection of these antigens may be useful for diagnostic purposes, and could help in distinguishing variants of the acute myeloblastic leukaemias. At the moment we are attempting to identify the nature of the normal marrow cells which show antigens common with leukaemic myeloblast but not found in splenic tissue. WVe hope that the antisera absorbed with spleen will help to provide markers for the physiological stages of myeloid differentiation. 493 One of the most striking positive findings in this study has been the high level of reactivity of antisera against allo-antigens. To some extent this may reflect the use of the K-cell cytotoxicity assay. This assay measures IgG antibody (MacLennan, 1972) whereas complementdependent cytolysis is activated more efficiently on a molar basis by IgM than IgG (Humphrey, 1967; Linscott, 1970) . The early screening of absorbed antisera in this study included complement-dependent as well as K-cell-dependent cytolysis. However, use of the former was discontinued after the second spleen cell absorption, as nearly all complementrevealed activity had been lost at that stage (Tupchong, 1978) . Rabbits have been used previously to raise antibody against human polymorphic antigens (Einstein et al., 1971 ), but, it does seem that further use of the rat K-cell assay for detecting xeno-antibodies against human HL-A antigens may be profitable.
